BA
BCRX icon

Bellwether Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bellwether Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-41,853
Closed -$601K – 564
2021
Q3 		$601K Buy
+41,853
New +$660K 0.2% 82

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Bellwether Advisors's BCRX Position: Q4 2021 in Review

Bellwether Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2021, closing a stake of 41,853 shares — an estimated $601K sold.

Bellwether Advisors first reported a position in BCRX in Q3 2021 and held it in 1 quarter. The position peaked at $601K in Q3 2021. 206 funds tracked by Wall St. Rank hold BCRX as of Q4 2021.

  • Bellwether Advisors reported no remaining BioCryst Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Bellwether Advisors sold 41,853 BioCryst Pharmaceuticals shares in Q4 2021, an estimated $601K.
  • Bellwether Advisors first reported a position in BioCryst Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Bellwether Advisors's BioCryst Pharmaceuticals position peaked at $601K in Q3 2021.
  • 206 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2021.

Based on Bellwether Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.